Sljedeći

Auto Play

Defining Progression in Metastatic Kidney Cancer

3 Pogledi • 06/26/23
Udio
Ugraditi
administrator
administrator
Pretplatnici
0

Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.

Prikaži više
0 Komentari sort Poredaj po
Komentari na Facebooku

Sljedeći

Auto Play